Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Launched by DUKE UNIVERSITY · Apr 13, 2015
Trial Information
Current as of November 02, 2025
Recruiting
Keywords
ClinConnect Summary
The CARRA Registry is an ongoing study that focuses on children and young adults with rheumatic joint diseases, which are conditions that cause pain and inflammation in the joints. This study aims to gather important information about these diseases and the treatments used to manage them. By collecting data from patients, the registry will help researchers answer key questions about the safety and effectiveness of different therapies for young people with these conditions.
To participate in this study, individuals must have been diagnosed with a rheumatic disease before the age of 16 for juvenile idiopathic arthritis (JIA) or before age 19 for other types of rheumatic diseases. Participants, or their parents or guardians, need to be able to give written consent and agree to future contact from the study team. The study is currently recruiting participants of all genders, but those over 21 years old are not eligible to join. If you or your child decide to participate, you can expect to provide information about your health and treatment, which will contribute to a better understanding of these diseases and how to treat them effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Onset of rheumatic disease prior to age 16 years for JIA and onset prior to age 19 years for all other rheumatic diseases (see appendix A).
- • 2. Subject (and/or parent/legal guardian when required) is able to provide written informed consent and willing to comply with study procedures.
- • 3. Subject and/or parent/legal guardian is willing to be contacted in the future by study staff.
- Exclusion Criteria:
- • 1\. Greater than 21 years of age at the time of enrollment.
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Kansas City, Kansas, United States
Ann Arbor, Michigan, United States
Birmingham, Alabama, United States
New York, New York, United States
New York, New York, United States
Indianapolis, Indiana, United States
Cleveland, Ohio, United States
Philadelphia, Pennsylvania, United States
Hackensack, New Jersey, United States
Kansas City, Missouri, United States
Norfolk, Virginia, United States
Cleveland, Ohio, United States
Jackson, Mississippi, United States
Hershey, Pennsylvania, United States
New Brunswick, New Jersey, United States
Cincinnati, Ohio, United States
Rochester, New York, United States
Birmingham, Alabama, United States
Boston, Massachusetts, United States
New York, New York, United States
Hartford, Connecticut, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Miami, Florida, United States
Augusta, Georgia, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Seattle, Washington, United States
San Juan, Puerto Rico
Chapel Hill, North Carolina, United States
Orlando, Florida, United States
Saint Petersburg, Florida, United States
San Diego, California, United States
Minneapolis, Minnesota, United States
Los Angeles, California, United States
Boston, Massachusetts, United States
Chicago, Illinois, United States
Burlington, Vermont, United States
Washington, District Of Columbia, United States
Providence, Rhode Island, United States
Palo Alto, California, United States
New Haven, Connecticut, United States
Saint Louis, Missouri, United States
Chicago, Illinois, United States
Akron, Ohio, United States
Toronto, Ontario, Canada
Durham, North Carolina, United States
Grand Rapids, Michigan, United States
New York, New York, United States
Grand Rapids, Michigan, United States
San Francisco, California, United States
Saint Louis, Missouri, United States
Phoenix, Arizona, United States
Nashville, Tennessee, United States
Portland, Oregon, United States
Fargo, North Dakota, United States
Lake Success, New York, United States
Wauwatosa, Wisconsin, United States
Aurora, Colorado, United States
Pittsburgh, Pennsylvania, United States
Morristown, New Jersey, United States
Boston, Massachusetts, United States
Charleston, South Carolina, United States
Fargo, North Dakota, United States
Los Angeles, California, United States
Gainesville, Florida, United States
Iowa City, Iowa, United States
Louisville, Kentucky, United States
Springfield, Massachusetts, United States
West Orange, New Jersey, United States
Albany, New York, United States
Charlotte, North Carolina, United States
Winston Salem, North Carolina, United States
Cleveland, Ohio, United States
Dallas, Texas, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Madison, Wisconsin, United States
Calgary, Alberta, Canada
Winnipeg, Manitoba, Canada
Halifax, Nova Scotia, Canada
Petach Tikva, Israel
Rome, Italy
St. Petersburg, Florida, United States
Washington D.C., District Of Columbia, United States
St Louis, Missouri, United States
St Louis, Missouri, United States
Petah Tikva, Israel
Patients applied
Trial Officials
Mara L Becker, MD, MSCE
Principal Investigator
Duke Clinical Research Insitute
Mary Beth Son, MD
Principal Investigator
Boston Children's Hospital
Timothy Beukelman, MD, MSCE
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials